From PCOS to PMOS
Polycystic Ovarian Syndrome has long been misunderstood and, in many ways, poorly represented by its name alone. Anyone living with, or supporting someone with, PCOS, knows that this condition extends far beyond the ovaries. It is a complex syndrome involving reproductive, hormonal, metabolic, and systemic changes that can impact nearly every aspect of health and wellbeing.
This week marked a significant shift in how we understand and discuss this condition. A landmark article published in The Lancet proposed a new name for PCOS following collaboration among leading experts in reproductive and endocrine health. Their goal was simple but important: to create terminology that more accurately reflects the true scope of a condition affecting an estimated 170 million people worldwide.
As a result, Polycystic Ovarian Syndrome is now known as Polyendocrine Metabolic Ovarian Syndrome (PMOS). This name that better acknowledges the broad hormonal and metabolic nature of the condition, rather than focusing solely on ovarian cysts.
Why Do We Need a New Name?
For years, PCOS has been a condition with an identity problem. The name Polycystic Ovarian Syndromesuggests a disorder centred around ovarian cysts, when in reality, the condition is far more complex and far-reaching.
1. “Polycystic” is Misleading
The term polycystic implies the presence of pathological ovarian cysts, but this is not actually what is seen in PCOS. The “cysts” are immature egg follicles. These are small fluid-filled sacs that develop during the ovulation process but do not fully mature or release an egg. These follicles are not dangerous and do not need to be surgically removed.
2. The Condition Extends Far Beyond the Ovaries
PCOS is not simply an ovarian condition. While it commonly involves ovulatory dysfunction, such as irregular ovulation or absent periods, it also affects multiple hormonal and metabolic systems throughout the body.
Symptoms can include:
Hirsutism (excess facial or body hair growth)
Acne
Male-pattern hair thinning or loss
Insulin resistance
Weight changes
Fatty liver disease
Dyslipidemia (abnormal cholesterol levels)
Hypertension (high blood pressure)
3. The Medical Community Has Outgrown the Original Name
Patients, advocacy groups, healthcare professionals, and researchers have been calling for a name change for years. When PCOS was first named, the condition was primarily identified by the appearance of multiple cyst-like structures on ultrasound. At the time, little was understood about its broader hormonal and metabolic implications.
Today, we know much more. The science has evolved, and many experts believe the terminology should evolve alongside it.
4. Names Shape Care
When a condition’s name does not accurately reflect its true nature, it can contribute to misunderstanding, delayed diagnosis, fragmented care, and significant knowledge gaps. Many people with PCOS spend years seeking answers or receiving treatment focused only on reproductive symptoms while metabolic and endocrine concerns go unrecognized.
The hope behind the transition to PMOS is that a more accurate name will improve awareness, research, diagnosis, and ultimately patient care.
How Did They Land on the Name PMOS?
The proposed name change was not decided by a small panel behind closed doors. It was developed through an extensive international process involving healthcare professionals, researchers, and people living with PCOS.
According to the publication:
“Survey A included responses from 9,358 people with PCOS and 3,656 health professionals. Twenty-seven people with PCOS and 63 health professionals participated in workshops, while Survey B included 1,053 people with PCOS and 293 health professionals, with broad global representation.”
Doctors, nurses, psychotherapists, researchers, and PCOS patients all contributed to the discussion, ensuring that lived experience was considered alongside scientific understanding.
Other Names That Were Considered
Several alternative names were explored before arriving at PMOS.
1. Metabolic Endocrine Reproductive Syndrome (MERS)
This was ultimately rejected because the acronym closely resembled Middle East Respiratory Syndrome (MERS), creating potential confusion.
2. Endocrine Metabolic Ovulatory Syndrome (EMOS)
This option initially ranked highly. However, concerns were raised about the acronym’s association with the “emo” subculture, leading researchers to reconsider its use.
After additional rounds of discussion and surveys, the term polyendocrine was added, resulting in the final proposed name:
Polyendocrine Metabolic Ovarian Syndrome (PMOS)
The name was selected because it more accurately reflects the condition’s widespread endocrine and metabolic involvement while still maintaining some familiarity with the original acronym, PCOS.
Will the Diagnostic Criteria Change?
At this time, the diagnostic criteria remain the same. Diagnosis still requires 2 out of 3 of the following features in adults (adolescents require the first two criteria only):
Ovulatory Dysfunction
Irregular ovulation
Skipped periods or absence of menstruation
2. Hyperandrogenism (Clinical or Biochemical)
Clinical signs may include:
Acne
Excess hair growth on the face, chest, or abdomen
Male-pattern hair loss
Biochemical evidence may include
Elevated testosterone levels on bloodwork
3. Polycystic Ovarian Morphology
Identified through:
Transvaginal or pelvic ultrasound
Elevated Anti-Müllerian Hormone (AMH) levels
What Happens Next?
So, what now?
The proposed shift from PCOS to PMOS represents more than just a name change. It signals a broader change in how this condition is understood. The authors of this article anticipate a transition period of approximately three years before the new terminology becomes fully integrated into healthcare systems.
The hope is that this updated terminology will lead to:
Greater public and professional awareness
More comprehensive research
Earlier and more accurate diagnosis
Improved policy and healthcare support
More complete, whole-person care for patients living with PMOS
While change may take time, the intention is clear: to better reflect the true complexity of this condition and improve the way it is recognized, researched, and treated.
Read more about it here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext
